Tailored screening according to a man’s predicted risks may improve the cost effectiveness of screening; however, robust evidence on the long-term effectiveness and cost effectiveness of these approaches is lacking.

Results The deterministic incremental cost-effectiveness ratio of PSMA PET/CT was estimated to be A $21,147/quality-adjusted life-year gained versus CT+WBBS, and A$36,231/quality-adjusted life-year gained versus CT alone.

Numerous cost-effectiveness analyses (CEAs) and technology appraisals (TAs) evaluating IO therapies have been recently published.

A cost effectiveness per month of survival of the two sequences analysis was performed: the cost per month for the nivolumab > cabozantinib sequence was 1738.60 whereas the cost for the other one was €1624.80.

Findings from ADAURA also allow reflection on other relevant topics of this field, such as optimal treatment indication and sequence, biomarkers for response, patterns of relapse, quality of life and cost-effectiveness.

Results Based on our review of the interview study, we identified the following attributes associated with selecting medicinal cannabis: effectiveness; chance of side effects; support from family, friends, and/or physicians; cost; and availability.

Noting, however, that “this combined use will lead to an increased number of patients undergoing a prostate biopsy,” they conclude: “Further work will be needed on the acceptability to patients and physicians of a combined test approach, the use of additional risk factors, and cost-effectiveness.” medwireNews is an independent medical news service provided by Springer Healthcare Ltd. © 2022 Springer Healthcare Ltd, part of the Springer Nature Group Lancet Oncol 2022; 23 : 428–438

However, in an accompanying comment, Francesco Montorsi and colleagues from IRCCS Ospedale San Raffaele in Milan, Italy, point out that “[t]he feasibility and cost-effectiveness of genomic testing to identify screening candidates in the overall population or in a subset of men at increased risk remains questionable.”

The team notes that cost-effectiveness analyses of this novel strategy are now underway. medwireNews is an independent medical news service provided by Springer Healthcare Ltd. © 2021 Springer Healthcare Ltd, part of the Springer Nature Group Lancet Oncol 2021; doi:10.1016/S1470-2045(21)00348-X

Medical oncology healthcare professionals often have conflicting opinions regarding the clinical effectiveness, patient experience, access to care, and financial impact of using telehealth video consultations, US research shows.

They note, however, that “further long-term studies are needed” to confirm their findings and also point out that a cost-effectiveness study on the HYPO-RT-PC data is underway. medwireNews is an independent medical news service provided by Springer Healthcare Ltd. © 2021 Springer Healthcare Ltd, part of the Springer Nature Group Lancet Oncol 2021; doi:10.1016/S1470-2045(20)30581-7

Secondary endpoints include OS, cost-effectiveness and QoL.

Writing in JAMA Oncology , Jie Wang (Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China) and co-researchers say that “NCC-GP150 […] could be used for bTMB estimation as a surrogate for WES-based TMB, noting that “NCC-GP150 with a smaller panel size and satisfactory performance may be more accessible for clinic use with superior cost-effectiveness.”

This chapter provides a detailed review of the place of the 5-hydroxytryptamine receptor antagonist palonosetron in the management of chemotherapy-induced nausea and vomiting. Summary Palonosetron has several pharmacologic characteristics that set it apart from first generation serotonin (5-hydroxytryptamine-3; 5-HT3) receptor antagonists, including much higher affinity for the 5-HT3 receptor and a longer plasma half-life (40 hours versus 5–12 hours). In terms of safety, while palonosetron has the same class-related adverse effects as first generation drugs, it is associated with significantly less mean QTc interval prolongation. Clinical trials demonstrated palonosetron to be associated with higher complete response rates for CINV in the delayed and overall, but not acute, phases, compared with first-generation 5-HT3 receptor antagonists. Palonosetron has demonstrated efficacy has part of triplet CINV prophylaxis regimens, in combination with aprepitant and dexamethasone, as well as in combination with olanzapine and dexamethasone. Cost-effectiveness studies have shown that while palonosetron was associated with higher acquisition and treatment costs than first-generation treatments, this was offset by reduced healthcare utilization for CINV, giving lower overall than those of other treatments. All guidelines recommend palonosetron as the 5-HT3 receptor antagonist of choice in moderately emetogenic chemotherapy, with guidelines for highly emetogenic chemotherapy recommending a three-drug combination, comprising a 5-HT3 receptor antagonist, dexamethasone and an NK1 receptor antagonist (or olanzapine). Schwartzberg L. In: Management of Chemotherapy-Induced Nausea and Vomiting . Edited by: Navari R. Springer International Publishing Switzerland 2016. doi: 10.1007/978-3-319-27016-6_4